RU2746926C2 - Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких - Google Patents

Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких Download PDF

Info

Publication number
RU2746926C2
RU2746926C2 RU2018146158A RU2018146158A RU2746926C2 RU 2746926 C2 RU2746926 C2 RU 2746926C2 RU 2018146158 A RU2018146158 A RU 2018146158A RU 2018146158 A RU2018146158 A RU 2018146158A RU 2746926 C2 RU2746926 C2 RU 2746926C2
Authority
RU
Russia
Prior art keywords
beta
tgf
seq
antibody
ser
Prior art date
Application number
RU2018146158A
Other languages
English (en)
Russian (ru)
Other versions
RU2018146158A (ru
RU2018146158A3 (https=
Inventor
Хелен Бон
Джоанн Элизабет Компсон
Кейт Луиз Диксон
Карл Брендан Дойл
Марк Эллис
Мария Маргарида Говейа Саншу
Реймонд Энтони Джапп
Лара Кеворкян
Дэниел Джон Лайтвуд
Диана Маршалл
Эндрю Чарльз Пэйн
Джозеф Майкл Дэвид Растрик
Моника-Сара Шульце
Элисон Тернер
Керри Луиз Тайсон
Original Assignee
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Срл filed Critical Юсб Биофарма Срл
Publication of RU2018146158A publication Critical patent/RU2018146158A/ru
Publication of RU2018146158A3 publication Critical patent/RU2018146158A3/ru
Application granted granted Critical
Publication of RU2746926C2 publication Critical patent/RU2746926C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018146158A 2016-06-08 2017-06-07 Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких RU2746926C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1610044.8 2016-06-08
GBGB1610044.8A GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies
PCT/EP2017/063796 WO2017211873A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis

Publications (3)

Publication Number Publication Date
RU2018146158A RU2018146158A (ru) 2020-07-09
RU2018146158A3 RU2018146158A3 (https=) 2020-07-09
RU2746926C2 true RU2746926C2 (ru) 2021-04-22

Family

ID=56508288

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018146158A RU2746926C2 (ru) 2016-06-08 2017-06-07 Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких

Country Status (20)

Country Link
US (2) US10766956B2 (https=)
EP (1) EP3468992A1 (https=)
JP (1) JP2019520818A (https=)
KR (1) KR20190015497A (https=)
CN (1) CN109311970A (https=)
AR (1) AR108779A1 (https=)
AU (1) AU2017276685A1 (https=)
BR (1) BR112018074869A2 (https=)
CA (1) CA3024011A1 (https=)
CL (1) CL2018003510A1 (https=)
CO (1) CO2018012513A2 (https=)
EA (1) EA201892774A1 (https=)
GB (1) GB201610044D0 (https=)
IL (1) IL263425A (https=)
MX (1) MX2018014376A (https=)
RU (1) RU2746926C2 (https=)
SG (1) SG11201810311WA (https=)
TW (1) TW201802115A (https=)
UY (1) UY37279A (https=)
WO (1) WO2017211873A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP2022548776A (ja) * 2019-09-19 2022-11-21 ノースウェスタン ユニバーシティ ヒト人工多能性幹細胞のための費用効果の高い培地およびプロトコル
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
TWI867190B (zh) * 2020-03-19 2024-12-21 美商建南德克公司 同功型選擇性抗-TGF-β抗體及其使用方法
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CA3199324A1 (en) * 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN112961240B (zh) * 2021-04-06 2022-07-05 明济生物制药（北京）有限公司 一种靶向TGF-β1的单克隆抗体及其与间充质干细胞外泌体的联合应用
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
US20250127716A1 (en) * 2022-02-04 2025-04-24 Justus-Liebig-Universitaet Giessen Inhaled imatinib for treatment of pulmonary hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
JP2009521496A (ja) 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
DK2083863T3 (da) * 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
SG195253A1 (en) * 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
PT2971048T (pt) 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LISA M. RICE et al., Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, J Clin Invest., 2015, Vol.125, N.7, pp.2795-2807. *
LISA M. RICE et al., Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, J Clin Invest., 2015, Vol.125, N.7, pp.2795-2807. ROSEMARY J. AKHURST et al., Targeting the TGFβ signalling pathway in disease, Nat Rev Drug Discov, 2012, Vol.11, N.10, pp.790-811. *
ROSEMARY J. AKHURST et al., Targeting the TGFβ signalling pathway in disease, Nat Rev Drug Discov, 2012, Vol.11, N.10, pp.790-811. *

Also Published As

Publication number Publication date
BR112018074869A2 (pt) 2019-03-26
GB201610044D0 (en) 2016-07-20
JP2019520818A (ja) 2019-07-25
CN109311970A (zh) 2019-02-05
EA201892774A1 (ru) 2019-05-31
AR108779A1 (es) 2018-09-26
TW201802115A (zh) 2018-01-16
CO2018012513A2 (es) 2019-02-08
SG11201810311WA (en) 2018-12-28
IL263425A (en) 2018-12-31
US10766956B2 (en) 2020-09-08
WO2017211873A1 (en) 2017-12-14
EP3468992A1 (en) 2019-04-17
KR20190015497A (ko) 2019-02-13
CL2018003510A1 (es) 2019-02-01
MX2018014376A (es) 2019-03-14
RU2018146158A (ru) 2020-07-09
US20200407436A1 (en) 2020-12-31
CA3024011A1 (en) 2017-12-14
AU2017276685A1 (en) 2018-11-29
US11518803B2 (en) 2022-12-06
RU2018146158A3 (https=) 2020-07-09
UY37279A (es) 2018-01-31
US20190330321A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
CN102892785B (zh) 生物学制品：人源化激动性抗-pd-1抗体
KR102742965B1 (ko) 타우 결합 항체
CN102892786B (zh) Pd-1抗体
JP6028737B2 (ja) Ｉｌ−１７ａとｉｌ−１７ｆに結合する抗体分子
US8057794B2 (en) Antibody molecules which bind to human IL-17
JP2021191758A (ja) 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
KR20110128922A (ko) 인간 ｉｌ-１３에 대한 결합 특이성을 갖는 항체 분자
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
HK1245810B (zh) Tau 结合抗体
HK1187929B (en) Antibody molecules which bind il-17a and il-17f
HK1187929A (en) Antibody molecules which bind il-17a and il-17f

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant